SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Dr. Andrés Rodríguez - 8 April, 2025 0

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Dr. Omar Tupayachi - 8 April, 2025 0

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Dr. Carlos Fava - 8 April, 2025 0

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad

Tag: Convalescent Plasma

Convalescent Plasma for Severe Pneumonia from COVID-19

Últimas Noticias

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Noticias Institucionales

April 9 – How to Apply for the SOLACI Research Grant 2025? Virtual Zoom Event

Watch our event on Evidence and Controversies of Renal Denervation in 2025

March 26 – SOLACI Webinar: Evidence and Controversies in Renal Denervation in 2025

Accesos